1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,176 | 0,187 | 22:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:18 | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 171 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 06.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 309 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 101 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| 27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL, A WHOLLY-OWNED SUBSIDIARY | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 3 | HKEx | ||
| 17.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | VIVA BIOTECH (01873): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 16.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,810 | -2,63 % | Valneva: Aktie trotzt negativen News | Die Aktie von Valneva kann sich auch zum Wochenstart gut behaupten. Trotz negativer News zum Chikungunya-Impfstoff IXCHIQ ist das Papier im Tagesverlauf auf der Handelsplattform Tradegate ins Plus gedreht.... ► Artikel lesen | |
| NOVONESIS | 59,96 | +1,22 % | Novonesis (Novozymes A/S): Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook | COPENHAGEN, Denmark - May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The... ► Artikel lesen | |
| GENMAB | 175,00 | +0,81 % | Genmab A/S: Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY) Development Program at the 2025 European Hematology Association (EHA) Congress | Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,712 | -4,71 % | Arbutus Biopharma Corp - 10-Q, Quarterly Report | ||
| BEIGENE LTD ADR | 202,00 | +2,54 % | BeiGene, Ltd.: BeiGene präsentiert neue Daten auf der EHA 2025, die die Stärke des Hämatologie-Portfolios, die Führungsrolle von BRUKINSA und Innovationen der nächsten Generation unterstreichen | Daten von 31 Abstracts verdeutlichen BeiGenes Engagement für die Transformation der Behandlung bösartiger B-Zell-Malignome In vier mündlichen Präsentationen werden aktualisierte Daten zum experimentellen... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,920 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update | Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date supports... ► Artikel lesen | |
| SINO BIOPHARM | 0,452 | +0,24 % | Kursgewinne für die Sino Biopharmaceutical-Aktie (0,46 €) | Das Wertpapier von Sino Biopharmaceutical notiert heute ein wenig fester. Das Papier notiert gegenwärtig bei 0,46 Euro. Ein Preisanstieg in Höhe von 0,0205 Euro erfreut derzeit die Aktionäre von Sino... ► Artikel lesen | |
| VERICEL | 37,000 | -2,63 % | Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance | Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 MillionApproximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,310 | +1,97 % | Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May... ► Artikel lesen | |
| ZAI LAB LTD ADR | 25,200 | -0,79 % | Zai Lab Limited Q1 Loss Decreases, Beats Estimates | BEIJING (dpa-AFX) - Zai Lab Limited (ZLAB) announced Loss for first quarter that decreased from last year and beat the Street estimates.The company's bottom line came in at -$48.438 million... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,754 | +11,21 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,365 | -100,00 % | BioXcel Therapeutics: Deutliche Verbesserung der Quartalszahlen trotz Umsatzrückgang | ||
| REGENXBIO | 7,200 | -4,00 % | REGENXBIO Inc.: REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II | FDA assigns PDUFA target action date of November 9, 2025
RGX-121 on track to be the first gene therapy and one-time treatment for MPS II
Partner Nippon Shinyaku... ► Artikel lesen | |
| AKEBIA | 2,202 | +0,09 % | Akebia projects Vafseo rollout to double patient access by Q4 2025 | ||
| CSTONE PHARMACEUTICALS | 0,290 | -9,38 % | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- ... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,006 (-3,08 %) liegt der Kurs bei 0,189 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.